Analyst Daina Graybosch from Leerink Partners maintained a Buy rating on Gilead Sciences and decreased the price target to $104.00 from $114.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daina Graybosch’s rating is based on Gilead Sciences’ strong financial performance in the second quarter of 2025, where the company exceeded expectations in both revenue and earnings. The standout factor was the promising indicators for the launch of Yeztugo, a new HIV pre-exposure prophylaxis treatment, which has already gained significant coverage from major state Medicaid and commercial plans. This positions Gilead well for a successful rollout, with management confident in achieving substantial coverage within six months post-launch.
Additionally, Gilead’s core HIV franchise, particularly Biktarvy and Descovy, demonstrated robust sales growth, contributing significantly to the company’s overall performance. The favorable market conditions for PrEP, alongside strategic efforts to secure access, further bolster the outlook for Gilead’s HIV treatments. Despite potential regulatory challenges, Graybosch believes that Gilead’s proactive measures will mitigate risks, supporting the Buy rating.
According to TipRanks, Graybosch is an analyst with an average return of -14.6% and a 33.86% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Merck & Company, and Summit Therapeutics.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $134.00 price target.